REPLY
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot and will showcase its transformative potential at the Milan 2024 Xchange event on May 15-16 through a live immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515336953/en/
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot. As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. (Graphic: Business Wire)
As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. A tailored roadmap, developed in collaboration with Microsoft, guides organisations through the implementation and maximisation of Copilot’s capabilities.
Understanding the importance of adoption, Reply has developed a five-step approach to ensure that the benefits of Copilot M365 are accessible to a wide corporate audience. This approach aligns with Microsoft AI Lab’s vision and focuses on integrating Copilot into daily operations effectively. The below Copilot maturity model framework aims to help customers assess their current state and their desired state with Copilot, and to identify the gaps and the actions needed to achieve their goals:
- Approach – Exploring the art of the possible, technical readiness and align with company strategy.
- Assess – Plan a pilot where we take the early-adopters on a journey with measurement qualitative and quantitative. Use those results to create a business case and roll-out plan.
- Adopt – Set-up a CoE for Copilot. Land key messages and provide training using a scenario/functional specific approach.
- Embed – Make Copilot Business as Usual at or your organisation. Manage a dynamic licensing approach and stay on top of new features.
- Extend – Bring the power of copilot to wider application.
Immersive Introduction at Milan Xchange
Held annually, Reply’s Xchange brings together technology leaders and innovators to explore the latest in digital solutions and strategies. This year, Reply will debut the “AI-Scape Room," an immersive virtual escape room experience developed by WM Reply and powered by Microsoft Copilot for Microsoft 365. This demonstration will highlight how Copilot enhances productivity, security, and collaboration within business processes through advanced AI integration.
The AI-Scape Room is designed to foster teamwork and communication as participants collaborate to solve puzzles and challenges with the assistance of Copilot’s AI-driven insights. The bespoke escape room is an opportunity for all participants to experience, explore and discover how to utilise M365 copilot as the hands-on challenges provide valuable insights into the potential of AI in enhancing workplace efficiency and engagement.
For more information on Reply’s M365 Copilot Adoption approach, the AI-Scape Room and Reply's AI-based solutions, visit: www.reply.com
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
WM REPLY
WM Reply is the Reply Group company specialising in improving employees day-to-day lives through modern workplace solutions and connecting consumers to products and experiences they love online. We support our clients from beginning to end; designing and building their solution and easing adoption. Making sure our clients are not just enjoying the benefits of the cloud but exploiting them as well. We are recognised as leaders within Sitecore, Dynamics 365, Office 365 and the products within such as SharePoint, Power Platform, Yammer and Microsoft Teams. A Microsoft Gold Partner five times over! We have a colourful team who are famous for their imagination, delivery, passion for technology and most importantly, their pride in delivery. www.wm.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515336953/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom